Status:
COMPLETED
Prospective Investigation of Antithrombin III Deficiency in Adult Patients With ECMO
Lead Sponsor:
Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital
Conditions:
Antithrombin III Deficiency
Extracorporeal Membrane Oxygenation Complication
Eligibility:
All Genders
18+ years
Brief Summary
There are publications showing a decrease in Antithrombin III levels of continuous flow and routine heparin therapy in adult patients undergoing Extracorporeal Membrane Oxygenation (ECMO) however, the...
Detailed Description
ECMO is applied in patients with acute severe heart or lung failure. The treatment protocol of patients undergoing ECMO is carefully arranged against the risk of bleeding / thrombosis. According to t...
Eligibility Criteria
Inclusion
- Being over the age of 18
- Patients with ECMO run for 3 days or more (to be able to determine at least 3 antithrombin 3 levels)
Exclusion
- Patients with ECMO run less than 3 days
Key Trial Info
Start Date :
January 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2022
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04879550
Start Date
January 1 2020
End Date
March 1 2022
Last Update
May 24 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Istanbul Dr.Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital
Istanbul, Turkey (Türkiye), 34668